Acetylcarnitine is a candidate diagnostic and prognostic biomarker of hepatocellular carcinoma

Cancer Research

Volumn 76, Issue 10, 2016, Pages 2912-2920

  Lu, Yonghai ^a   Li, Ning ^b   Gao, Liang ^a   Xu, Yong Jiang ^c   Huang, Chong ^b   Yu, Kangkang ^b   Ling, Qingxia ^b   Cheng, Qi ^b   Chen, Shengsen ^b   Zhu, Mengqi ^b   Fang, Jinling ^a   Chen, Mingquan ^b   Ong, Choon Nam ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b FUDAN UNIVERSITY   (China)

^c INSTITUTE OF PLANT PHYSIOLOGY AND ECOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCARNITINE; BIOLOGICAL MARKER; TUMOR MARKER;

ADULT; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; BLOOD SAMPLING; CANCER DIAGNOSIS; CANCER GRADING; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; LIVER; LIVER CELL CARCINOMA; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; BLOOD; CANCER STAGING; CARCINOMA, HEPATOCELLULAR; CASE CONTROL STUDY; COMPARATIVE STUDY; ENZYME IMMUNOASSAY; FOLLOW UP; LIVER CIRRHOSIS; LIVER NEOPLASMS; METABOLOME; METABOLOMICS; MIDDLE AGED; PROGNOSIS; SURVIVAL RATE;

ACETYLCARNITINE; ADULT; AGED; BIOMARKERS, TUMOR; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MASS SPECTROMETRY; METABOLOME; METABOLOMICS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE;

EID: 84971570096     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-15-3199     Document Type: Article

References (44)

1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterology 2007;132:2557-76.
2. Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat Rev Cancer 2011;11:85-95.
3. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-917.
4. Bialecki ES, Di Bisceglie AM. Diagnosis of hepatocellular carcinoma. HPB 2005;7:26-34.
5. Forner A, Bruix J. Biomarkers for early diagnosis of hepatocellular carcinoma. Lancet Oncol 2012;13:750-1.
6. Taketa K. Alpha-Fetoprotein: reevaluation in Hepatology. Hepatology 1990;12:1420-32.
7. Okabe H, Satoh S, Kato T, Kitahara O, Yanagawa R, Yamaoka Y, et al. Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: Identification of genes involved in viral carcinogenesis and tumor progression. Cancer Res 2001;61:2129-37.
8. Ye QH, Qin LX, Forgues M, He P, Kim JW, Peng AC, et al. Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med 2003;9: 416-23.
9. Tarhuni A, Guyot E, Rufat P, Sutton A, Bourcier V, Grando V, et al. Impact of cytokine gene variants on the prediction and prognosis of hepatocellular carcinoma in patients with cirrhosis. J Hepatol 2014;61:342-50.
10. Borel F, Konstantinova P, Jansen PL. Diagnostic and therapeutic potential of miRNA signatures in patients with hepatocellular carcinoma. J Hepatol 2012;56:1371-83.
11. Liu S, Guo W, Shi J, Li N, Yu X, Xue J, et al. MicroRNA-135a contributes to the development of portal vein tumor thrombus by promoting metastasis in hepatocellular carcinoma. J Hepatol 2012;56:389-96.
12. Codarin E, Renzone G, Poz A, Avellini C, Baccarani U, Lupo F, et al. Differential proteomic analysis of subfractioned human hepatocellular carcinoma tissues. J Proteome Res 2009;8:2273-84.
13. Nicholson JK, Holmes E, Kinross JM, Darzi AW, Takats Z, Lindon JC. Metabolic phenotyping in clinical and surgical environments. Nature 2012;491:384-92.
14. Wang X, Zhang A, Sun H. Power of metabolomics in diagnosis and biomarker discovery of hepatocellular carcinoma. Hepatology 2013;57: 2072-7.
15. Xue R, Lin Z, Deng C, Dong L, Liu T, Wang J, et al. A serum metabolomic investigation on hepatocellular carcinoma patients by chemical derivatization followed by gas chromatography/mass spectrometry. Rapid Commun Mass Spectrom 2008;22:3061-8.
16. Chen F, Xue JH, Zhou LF, Wu SS, Chen Z. Identification of serum biomarkers of hepatocarcinoma through liquid chromatography/mass spectrometry-based metabonomicmethod. Anal Bioanal Chem 2011;401: 1899-904.
17. Xiao JF, Varghese RS, Zhou B, Ranjbar MRN, Zhao Y, Tsai TH, et al. LC-MS based serum metabolomics for identification of hepatocellular carcinoma biomarkers in Egyptian cohort. J Proteome Res 2012;11:5914-23.
18. Shariff MIF, Ladep NG, Cox IJ, Williams HRT, Okeke E, Malu A, et al. Characterization of urinary biomarkers of hepatocellular carcinoma using magnetic resonance spectroscopy in aNigerian population. J Proteome Res 2010;9:1096-103.
19. Wang XJ, Zhang AH, Han Y, Wang P, Sun H, Song GC, et al. Urine metabolomics analysis for biomarker discovery and detection of jaundice syndrome in patients with liver disease. Mol Cell Proteomics 2012;11: 370-80.
20. Shariff MIF, Gomaa AI, Cox IJ, Patel M, Williams HRT, Crossey MME, et al. Urinary metabolic biomarkers of hepatocellular carcinoma in an Egyptian population: A validation study. J Proteome Res 2011;10:1828-36.
21. Nahon P, Amathieu R, Triba MN, Bouchemal N, Nault JC, Ziol M, et al. Identification of serum proton NMR metabolomic fingerprints associated with hepatocellular carcinoma in patients with alcoholic cirrhosis. Clin Cancer Res 2012;18:6714-22.
22. Chen T, Xie G, Wang X, Fan J, Qiu Y, Zheng X, et al. Serum and urine metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma. Mol Cell Proteomics 2011;10:M110.004945.
23. Huang Q, Tan YX, Yin PY, Ye GZ, Gao P, Lu X, et al. Metabolic characterization of hepatocellular carcinoma using nontargeted tissue metabolomics. Cancer Res 2013;73:4992-5002.
24. Beyoglu D, Imbeaud S, Maurhofer O, Bioulac-Sage P, Zucman-Rossi J, Dufour JF, et al. Tissue metabolomics of hepatocellular carcinoma: Tumor energy metabolism and the role of transcriptomic classification. Hepatology 2013;58:229-38.
25. Gao YH, Lu YH, Huang SM, Gao L, Liang XX, Wu YN, et al. Identifying early urinary metabolic changes with long-term environmental exposure to cadmiumby mass-spectrometry-basedmetabolomics. Environ Sci Technol 2014;48:6409-18.
26. Kamleh MA, Ebbels TM, Spagou K, Masson P, Want EJ. Optimizing the use of quality control samples for signal drift correction in large-scale urine metabolic profiling studies. Anal Chem 2012;84:2670-7.
27. Bijlsma S, Bobeldijk I, Verheij ER, Ramaker R, Kochhar S, Macdonald IA, et al. Large-scale human metabolomics studies: A strategy for data (pre-) processing and validation. Anal Chem 2006;78:567-74.
28. Smilde AK, van der Werf MJ, Bijlsma S, van der Werff-van der Vat BJ, Jellema RH. Fusion of mass spectrometry-based metabolomics data. Anal Chem 2005;77:6729-36.
29. Zeng J, Yin PY, Tan YX, Dong LW, Hu CX, Huang Q, et al. Metabolomics study of hepatocellular carcinoma: Discovery and validation of serum potential biomarkers by using capillary electrophoresis-mass spectrometry. J Proteome Res 2014;13:3420-31.
30. Shen QJ, Fan J, Yang XR, Tan YX, Zhao WF, Xu Y, et al. Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: A largescale, multicentre study. Lancet Oncol 2012;13:817-26.
31. Warburg O. On the origin of cancer cells. Science 1956;123:309-14.
32. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer 2004;4:891-9.
33. Christensen HN. Role of amino acid transport and countertransport in nutrition and metabolism. Physiol Rev 1990;70:43-77.
34. Fitian AI, Nelson DR, Liu C, Xu Y, Ararat M, Cabrera R. Integrated metabolomic profiling of hepatocellular carcinoma in hepatitis C cirrhosis through GC/MS and UPLC/MS-MS. Liver Int 2014;34:1428-44.
35. Hong Y, Ho KS, Eu KW, Cheah PY. A susceptibility gene set for early onset colorectal cancer that integrates diverse signaling pathways: Implication for tumorigenesis. Clin Cancer Res 2007;13:1107-14.
36. Dang CV. Links between metabolism and cancer. Genes Dev 2012;26: 877-90.
37. Cantor JR, Sabatini DM. Cancer cell metabolism: One hallmark, many faces. Cancer Discov 2012;2:881-98.
38. Liu Y. Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer. Prostate Cancer Prostatic Dis 2006;9:230-4.
39. Zhou L, Wang Q, Yin P, Xing W, Wu Z, Chen S, et al. Serum metabolomics reveals the deregulation of fatty acids metabolism in hepatocellular carcinoma and chronic liver diseases. Anal Bioanal Chem 2012;403:203-13.
40. Linher-Melville K, Zantinge S, Sanli T, Gerstein H, Tsakiridis T, Singh G. Establishing a relationship between prolactin and altered fatty acid b-Oxidation via carnitine palmitoyl transferase 1 in breast cancer cells. BMC Cancer 2011;11:56.
41. Amodio P, Angeli P, Merkel C, Menon F, Gatta A. Plasma carnitine levels in liver cirrhosis: relationship with nutritional status and liver damage. J Clin Chem Clin Biochem 1990;28:619-26.
42. Hoppel C. The role of carnitine in normal and altered fatty acid metabolism. Am J Kidney Dis 2003;41:S4-12.
43. Malaguarnera M, Risino C, Gargante MP, Oreste G, Barone G, Tomasello AV, et al. Decrease of serum carnitine levels in patients with or without gastrointestinal cancer cachexia. World J Gastroentero 2006;12:4541-5.
44. Vinci E, Rampello E, Zanoli L, Oreste G, Pistone G, Malaguarnera M. Serum carnitine levels in patients with tumoral cachexia. Eur J Intern Med 2005;16:419-23.